Friday, March 27, 2015 Last update: 4:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

AcelRx Pharmaceuticals, Inc.

News articles for AcelRx Pharmaceuticals, Inc.:

Friday, March 20, 2015

  • AcelRx Appoints Howard B. Rosen as Interim CEO
    REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April ... read more

Monday, March 16, 2015

Monday, March 9, 2015

  • AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
    REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three and twelve months ended December 31, 2014. Fourth Quarter 2014 Financial ... read more
  • AcelRx Provides Regulatory Update on Zalviso
    REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and potential content of the resubmission of the New Drug ... read more

Wednesday, March 4, 2015

Friday, February 20, 2015

  • AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
    REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at ... read more

Wednesday, February 4, 2015

  • AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
    REDWOOD CITY, Calif., Feb. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company ... read more

Tuesday, December 2, 2014

  • AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
    REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the ... read more

Thursday, November 20, 2014

  • AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events
    REDWOOD CITY, Calif., Nov. 20, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at Piper Jaffray, RBC, Guggenheim ... read more

Thursday, November 13, 2014

Monday, November 10, 2014

Friday, November 7, 2014

  • AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
    REDWOOD CITY, Calif., Nov. 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at the Credit Suisse Annual ... read more

Thursday, November 6, 2014

Wednesday, November 5, 2014

  • Acelrx Pharmaceuticals Announces Management Change
    REDWOOD CITY, Calif., Nov. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard King, the Company's CEO and President. ... read more

Monday, October 27, 2014

Wednesday, October 22, 2014

  • AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
    REDWOOD CITY, Calif., Oct. 22, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the IAP310 study have been published in Regional Anesthesia and Pain Medicine (RAPM), a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3 ... read more

Thursday, October 16, 2014

Friday, October 10, 2014

Monday, October 6, 2014